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DOI 10.1186/s13063-015-0622-4STUDY PROTOCOL Open AccessLaser therapy for onychomycosis in patients
with diabetes at risk for foot complications: study
protocol for a randomized, double-blind,
controlled trial (LASER-1)
Leonie Nijenhuis-Rosien1,2*, Nanne Kleefstra1,3,4, Maurice J Wolfhagen5, Klaas H Groenier1,6, Henk JG Bilo1,3,6
and Gijs WD Landman1,7Abstract
Background: In a sham-controlled double-blind trial, we aim to establish the efficacy and safety of the local application
of laser therapy in patients with diabetes, onychomycosis and risk factors for diabetes-related foot complications.
Onychomycosis leads to thickened and distorted nails, which in turn lead to increased local pressure. The combination of
onychomycosis and neuropathy or peripheral arterial disease (PAD) increases the risk of developing diabetes-related foot
complications. Usual care for high-risk patients with diabetes and onychomycosis is completely symptomatic with
frequent shaving and clipping of the nails. No effective curative local therapies exist, and systemic agents are often
withheld due to concerns for side effects and interactions.
Methods/Design: The primary aim is to evaluate the efficacy of four sessions of Nd:YAG 1064 nM laser application on
the one-year clinical and microbiological cure rate in a randomized, double-blind, sham-controlled design with blinded
outcome assessment. Mandatory inclusion criteria are diagnosis of diabetes, risk factors for developing foot ulcers defined
as a modified Simm’s classification score 1 or 2 and either neuropathy or PAD. A total of 64 patients are randomized to
intervention or sham treatment performed by a podiatrist.
Discussion: This study will be the first double-blind study that investigates the effects of local laser therapy on
onychomycosis, specifically performed in patients with diabetes with additional risk factors for foot complications.
Trial registration: Clinical trials.gov as NCT01996995, first received 22 November 2013.
Keywords: Onychomycosis, Nd:YAG laser, Diabetic foot, Diabetic foot ulcerBackground
The prevalence of onychomycosis is 2.5 to 2.8 times
higher in patients with diabetes [1-3]. The combination
of onychomycosis with other risk factors, like neur-
opathy, increases the risk of developing diabetes-related
foot complications [4]. Onychomycosis leads to thicken-
ing and sharpening of the nails. Thickening of the nails
potentially increases subungual pressure and compro-
mises vascular flow [5,6]. Sharpening of the nails can* Correspondence: l.nijenhuis@isala.nl
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article, unless otherwise stated.lead to small skin injuries, which are potential portals of
entry for pathogens. In the presence of neuropathy and/
or peripheral arterial disease (PAD), onychomycosis is
an additive risk factor for diabetes-related foot complica-
tions like foot ulcers, cellulitis, osteomyelitis and gan-
grene [7-10]. Worldwide, foot ulcers in patients with
diabetes are the leading cause of hospitalizations and
amputations [11-15]. The development of foot ulcers has
been associated with considerable disability [16-18], and
the presence of onychomycosis has been associated with
various emotional and social problems [19-23].
Treating onychomycosis is increasingly recognized as
a potential strategy for preventing diabetes-related foot
complications [5,24-26]. As part of the national Dutchd Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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mycosis is symptomatic; every six weeks, nails are skived
to normal proportions and sharp edges are clipped and
removed. This podiatric treatment aims to prevent ulcer
formation and the development of infections through re-
ducing subungual pressure and sharpen nails. Although
effective systemic antifungal agents are available, they
are often withheld due to concerns of side effects and in-
teractions [27]. Furthermore, studies that investigated
antifungal agents mostly excluded patients with diabetes.
Despite many claims of efficacy, no proven effective local
therapies exist. An effective and safe curative treatment
option for onychomycosis could lead to a decrease in
diabetes-related foot complications, especially in patients
with other risk factors. By reducing the frequency of
‘skiving and clipping’ treatment sessions and by reducing
the development of ulcers and infections caused by
treatment-resistant onychomycosis, local therapies could
become valuable preventive treatment option [28].
Local laser therapy is becoming increasingly popular
as a treatment modality for a variety of dermatologic
conditions and is being applied in the treatment of ony-
chomycosis [29]. The use of lasers for improving toenail
appearance has become one of the most rapidly ap-
proved therapies by the US Food and Drug Administra-
tion (FDA) [29]. Unlike pharmacologic agents, laser
systems are presumed to have predictable adverse effects
[29]. There are few nonrandomized trials and very few
randomized studies investigating effect of laser therapy
on onychomycosis. None had a double-blind design, and
none were performed in patients with diabetes who also
had additional risk factors for foot ulcers [29].
The primary aim of this trial is to evaluate the efficacy
of four sessions of N-YAG 1064nM laser application on
the one-year complete cure rate of onychomycosis in pa-
tients with diabetes and risk factors for developing dia-
betes related foot complications. Secondary outcomes
are microbiologic cure rate and improvement in health-
related quality of life (HRQOL).
Methods/Design
Primary and secondary care patients with type 1 and type
2 diabetes mellitus with risk factors for developing dia-
betic foot ulcers and a clinical suspicion of onychomycosis
will be recruited from a single-center podiatry practice.
Patients will be included after written informed consent
and microbiologic confirmation of onychomycosis.
Nail dust is collected from the target nail for microbio-
logic confirmation with blankophor microscopy, culture
and polymerase chain reaction (PCR). PCR is regarded
as the gold standard. The PCR is a real-time multiplex
PCR based on amplification of ribosomal internal tran-
scribed spacer regions and identification by probes spe-
cific for Trichophyton mentagrophytes species complex,Trichophyton tonsurans, Trichophyton violaceum, Tricho-
phyton rubrum species complex, Microsporum canis,
Microsporum audouinii and Epidermophyton floccosum
as described by Arabatzis et al. [30].
The target nail is the nail with the highest onychomy-
cosis severity index. The severity of onychomycosis is
evaluated with the onychomycosis severity index (OSI)
and standardized photographs are made [31]. Evaluation
of treatment results will be done by an independent ex-
pert panel blinded for treatment allocation. The three
experts are experienced health care providers who have
experience in the treatment of patients with diabetic foot
problems. Health-related quality of life (HRQOl) is eval-
uated at baseline and after follow-up with a generic
questionnaire, the WHO-5, and a disease specific ques-
tionnaire the NailQOl [23]. The trial has received re-
search ethics board approval from METC Isala Zwolle
(NL46084.075.13/METC nr 13.0885).
Study endpoints
The primary endpoint is complete cure rate of the target
nail. Complete cure is defined as a completely normal nail,
or negative microbiological results in case minor abnor-
malities are present. A minor abnormality is defined as an
irregularity of the nails with less than 5% of the surface
area of the target nail at less than 1/4 of the distance of
the distal nail edge without hyperkeratosis. Secondary
endpoints are microbiologic cure rate of the target nail,
complete clinical cure of all affected toes, complete clin-
ical cure of the target nail, markedly clinically improve-
ment of the target nail, onychomycosis severity index
below 6 (in patients with scores >6 at study entry) of the
target nail, changes in the affected surface of the target
nail, changes in affected surface of all nails with a clinical
diagnose of infection, free of subungual hyperkeratosis
and changes in HRQOL. A ‘markedly clinical nail im-
provement’ is defined as a nail with less than 10% abnor-
malities and without hyperkeratosis after 52 weeks.
Patient selection criteria
Patients with clinical suspicion and microbiologic con-
firmation of onychomycosis are randomized to laser
treatment or sham, see Figure 1.
Mandatory inclusion criteria are diagnosis of T1DM
or T2DM, 18 years or older, at risk for diabetic foot ul-
cers defined by a modified Simm’s classification score 1
or 2 with either neuropathy or PAD [32], and nail in-
volvement of at least 25% of the target nail [3]. See
Table 1 for the modified Simm’s classification.
Exclusion criteria are no microbiologic confirmation,
Simms’ classification score 3, the presence or history
of diabetic foot ulcers, ischemic pain, ankle brachial
index <0.9, patients receiving dialysis, severe renal in-
sufficiently (eGFR below 30 ml/min), a documented
Figure 1 Study flow chart.
Nijenhuis-Rosien et al. Trials  (2015) 16:108 Page 3 of 5toe pressure below 50 mmHg, use of systemic or topical
antifungal agents 3 months prior to inclusion, use of im-
munosuppressive drugs, presence of psoriasis, lichen pla-
nus, or other abnormalities that could result in clinically
abnormal toenails, a history of epilepsy and insufficient
knowledge of the Dutch language. Patients with a dark skin
color (Fitzpatrick 4 and 5) are excluded since dark skin
color is associated with dark nails, which theoretically lead
to increased temperatures during laser application [33].
Treatment assignment
Patients will be randomized in blocks using sealed nontran-
sparent envelopes to either laser or sham treatment. A cloth
between the head and his or her feet and a blinded goggle(which also protects the eyes) is used for blinding the sub-
jects. The periprocedural sounds and lights during the laser
application and the sham procedure are identical. The inves-
tigators are blinded for treatment allocation through the use
of an independent second podiatrist who performs the inter-
ventions. An independent three-person panel blinded for
treatment allocation evaluates the study outcomes using
standardized photographs made at baseline, week 30 and at
the end of follow-up. When consensus cannot be reached,
decisions are made through majority voting.
Clinical follow-up
Patients are treated with laser session in week 0, 2, 4, and
12. The settings are; 1064 nm, spot size 3 mm, 20 J /cm2,
Table 1 The modified Simms’ classification
Simm’s
classification
Risk profile Control frequency
Simm’s 0 No loss of PS or PAV Once in 12 months
Simm’s 1 Loss of PS or PAD, Without signs
of local increased pressure
Once in 6 months
Simm’s 2 Loss of PS and PAD. Loss of PS
and/or PAD in combination
with signs of local increased
pressure.
Once in 3 months
Simm’s 3 Ulcer or amputation in the
medical history
Once in 1 to 3 months
PAD, peripheral arterial disease; PS, protective sensibility.
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(one session on the horizontal and one the vertical pass-
ing) will be applied to eliminate potential safety issues in
those patients with a lack protective sensibility.
After 52 weeks, complete regrowth of the nail can be
expected. At baseline, 30 and 52 weeks all target nails
are sampled for blankophor microscopy, culture and
polymerase chain reaction.
At baseline, 30 and 52 weeks, all nails are evaluated
using the following scale: completely healed, markedly
improved (less than 10% affected), minor improvement,
unchanged, and worse, and with the onychomycosis se-
verity index [31]. The microbiological outcomes from
week 30 are used to differentiate re-infection from per-
sistent infection. Patients with re-infection have negative
microbiological results at week 30 and positive results at
week 52. Patients in whom different organisms at base-
line and week 30 or 52 are isolated are regarded as hav-
ing a reinfection. Patients are regarded as having a
persistent infection when baseline, week 30 and week 52
microbiological results provide evidence of the same or-
ganism. Week 52 results, including the microbiological
results, are used for evaluation of the primary and sec-
ondary outcomes. See Table 2 for the follow-up survey.
Data analysis
Estimating the proportion of patients with a complete
cure rate to be 40% in the intervention group and 5% in
the control group [27], with a power of 0.85, an alpha ofTable 2 Follow-up survey







Treatment x x0.05 (2-tailed), the sample size should be at least 56. Ac-
counting for loss to follow-up, the total sample size will
be aimed at 64.
Data entry is done in duplicate by persons not otherwise
involved in the study. All statistical analyses are carried
out by a statistician blinded for treatment allocation. The
Fisher’s Exact test will be used to test for differences be-
tween the treatment groups, and 95% confidence intervals
(CIs) will be constructed for the differences in clinical and
microbial cure rates. Normally distributed continuous var-
iables will be compared using the Student t-test, and non-
normally distributed variables will be compared with the
Mann-Whitney U test. A significance level of less than 5%
is regarded as significant. Analyses will be performed ac-
cording to the intention-to-treat principle. Separate per-
protocol analyses are planned in patients in whom all
treatment sessions are performed and for analyses exclud-
ing re-infection. A sensitivity analysis is planned that
regards completely cured patients at week 30 who have a
new infection at week 52 as having a complete cure. All
endpoints are evaluated at week 52.
Discussion
Patients with diabetes who suffer from onychomycosis
and neuropathy or PAD have an increased risk for devel-
oping diabetes-related foot complications, but also for
treatment-related complications. New, effective and safe
treatment modalities are needed for patients with dia-
betes who have risk factors for diabetes-related foot
complications, in order to minimize the risks of develop-
ing ulcers and also to minimize discomfort and
treatment-related complications caused by the current
usual care.
The results of this study will provide the first double-
blinded evidence for laser therapy and the first study in
patients with diabetes mellitus with risk factors for de-
veloping diabetic foot ulcers. Positive results could aid in
the prevention of diabetes-related foot complications
since no local curative options are available, and sys-
temic treatment could be avoided. If the results were to
show safety and efficacy of laser therapy, this would pro-
vide the first high-level evidence for efficacy of a localk 2 Week 4 Week 12 Week 30 Week 52
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of this study will be at least equally relevant if they were
to show non-efficacy since the use of lasers is becoming
increasingly popular. In that case, unnecessary laser ap-




CI: confidence intervals; FDA: Food and Drug Administration; HRQOL: health-
related quality of life; OSI: Onychomycosis Severity Index; PAD: peripheral
arterial disease; PCR: polymerase chain reaction; QoL: quality of life.
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